WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 529512
CAS#: 627085-11-4 (free base)
Description: OT-551 is a NF-κB inhibitor potentially for the treatment of cataracts and age-related macular degeneration.
MedKoo Cat#: 529512
Name: OT-551
CAS#: 627085-11-4 (free base)
Chemical Formula: C13H23NO3
Exact Mass:
Molecular Weight: 241.33
Elemental Analysis: C, 64.70; H, 9.61; N, 5.80; O, 19.89
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 627085-15-8 (HCl) 627085-11-4 (free base)
Synonym: OT-551; CPC-551; OT 551; CPC 551; OT551; CPC551
IUPAC/Chemical Name: 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl cyclopropanecarboxylate
InChi Key: ZWEXEKJLDHNLLA-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3
SMILES Code: O=C(C1CC1)OC2CC(C)(C)N(O)C(C)(C)C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 241.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, Cukras C, Chew EY, Sadda SR, Ferris FL. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131-9. doi: 10.1167/iovs.10-5637. PubMed PMID: 20574018; PubMed Central PMCID: PMC3055748.
2: Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats. Exp Eye Res. 2010 Jul;91(1):111-4. doi: 10.1016/j.exer.2010.04.012. PubMed PMID: 20434439; PubMed Central PMCID: PMC3175818.
3: Zarling JA, Brunt VE, Vallerga AK, Li W, Tao A, Zarling DA, Minson CT. Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. doi: 10.3389/fgene.2015.00325. Review. PubMed PMID: 26594225; PubMed Central PMCID: PMC4635221.
4: Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1900-5. PubMed PMID: 17389526.
5: Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Sep;6(5):565-79. doi: 10.1586/17512433.2013.829645. Review. PubMed PMID: 23971874.
6: Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009;223(6):401-10. doi: 10.1159/000228926. Review. PubMed PMID: 19622904.
